![]() |
Name |
Stemphypyrone
|
Molecular Formula | C12H16O4 | |
IUPAC Name* |
6-[(E)-4-hydroxypent-2-en-2-yl]-4-methoxy-3-methylpyran-2-one
|
|
SMILES |
CC1=C(C=C(OC1=O)/C(=C/C(C)O)/C)OC
|
|
InChI |
InChI=1S/C12H16O4/c1-7(5-8(2)13)10-6-11(15-4)9(3)12(14)16-10/h5-6,8,13H,1-4H3/b7-5+
|
|
InChIKey |
FXQRSXWMFRVMOS-FNORWQNLSA-N
|
|
Synonyms |
Stemphypyrone; stemphpyrone; CHEMBL560246; ACon1_002395; NCGC00169886-01; BRD-A13405028-001-01-9
|
|
CAS | NA | |
PubChem CID | 24041595 | |
ChEMBL ID | CHEMBL560246 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 224.25 | ALogp: | 1.6 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.856 |
Caco-2 Permeability: | -4.698 | MDCK Permeability: | 0.00002980 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.028 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.871 |
Blood-Brain-Barrier Penetration (BBB): | 0.351 | Plasma Protein Binding (PPB): | 77.89% |
Volume Distribution (VD): | 0.9 | Fu: | 30.93% |
CYP1A2-inhibitor: | 0.904 | CYP1A2-substrate: | 0.92 |
CYP2C19-inhibitor: | 0.579 | CYP2C19-substrate: | 0.83 |
CYP2C9-inhibitor: | 0.223 | CYP2C9-substrate: | 0.657 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.656 |
CYP3A4-inhibitor: | 0.044 | CYP3A4-substrate: | 0.383 |
Clearance (CL): | 6.135 | Half-life (T1/2): | 0.732 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.445 |
Drug-inuced Liver Injury (DILI): | 0.637 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.126 | Maximum Recommended Daily Dose: | 0.141 |
Skin Sensitization: | 0.097 | Carcinogencity: | 0.349 |
Eye Corrosion: | 0.069 | Eye Irritation: | 0.562 |
Respiratory Toxicity: | 0.059 |